share_log

歌禮製藥-B：二零二四年股東週年大會之代表委任表格

ASCLETIS-B: Form of Proxy for the 2024 Annual General Meeting

Hong Kong Stock Exchange ·  Apr 26 04:55
Summary by Moomoo AI
歌禮製藥有限公司（「本公司」）將於2024年5月23日舉行股東週年大會，地點為中國浙江省杭州市蕭山區啟迪路198號杭州灣信息港D座11樓。大會將考慮包括審核綜合財務報表、董事會報告與核數師報告在內的多項決議案。此外，會議議程還包括重選獨立非執行董事、授權董事會釐定董事酬金、續聘畢馬威會計師事務所為核數師及授權董事會釐定其酬金。股東將授予董事一般授權，以配發、發行及處理不超過已發行股份總數20%的股份，以及購回不超過已發行股份總數10%的股份。股東亦將考慮加上購回股份數目以擴大發行新股份的一般授權。股東可委任代表出席大會並投票，代表委任表格必須於大會前至少48小時送達本公司香港股份過戶登記分處。
歌禮製藥有限公司（「本公司」）將於2024年5月23日舉行股東週年大會，地點為中國浙江省杭州市蕭山區啟迪路198號杭州灣信息港D座11樓。大會將考慮包括審核綜合財務報表、董事會報告與核數師報告在內的多項決議案。此外，會議議程還包括重選獨立非執行董事、授權董事會釐定董事酬金、續聘畢馬威會計師事務所為核數師及授權董事會釐定其酬金。股東將授予董事一般授權，以配發、發行及處理不超過已發行股份總數20%的股份，以及購回不超過已發行股份總數10%的股份。股東亦將考慮加上購回股份數目以擴大發行新股份的一般授權。股東可委任代表出席大會並投票，代表委任表格必須於大會前至少48小時送達本公司香港股份過戶登記分處。
Song Pharmaceutical Co., Ltd. (the “Company”) will hold its Annual General Meeting on 23 May 2024 at the 11th floor of Tower D of Hangzhou Bay Information Port, 198 Qaidi Road, Xiaoshan District, Hangzhou City, Zhejiang Province, China. The General Meeting will consider a number of resolutions including the audit of the consolidated financial statements, the Board's report and the auditor's report. In addition, the agenda includes the re-election of independent non-executive directors, authorizing the Board of Directors to determine directors' remuneration, the renewal of the KPMG firm as auditor, and authorizing the Board to determine its remuneration. Shareholders will grant the Director general authority to distribute, issue and process shares not exceeding 20% of the total issued shares and to...Show More
Song Pharmaceutical Co., Ltd. (the “Company”) will hold its Annual General Meeting on 23 May 2024 at the 11th floor of Tower D of Hangzhou Bay Information Port, 198 Qaidi Road, Xiaoshan District, Hangzhou City, Zhejiang Province, China. The General Meeting will consider a number of resolutions including the audit of the consolidated financial statements, the Board's report and the auditor's report. In addition, the agenda includes the re-election of independent non-executive directors, authorizing the Board of Directors to determine directors' remuneration, the renewal of the KPMG firm as auditor, and authorizing the Board to determine its remuneration. Shareholders will grant the Director general authority to distribute, issue and process shares not exceeding 20% of the total issued shares and to repurchase shares not exceeding 10% of the total issued shares. Shareholders will also consider adding the number of repurchases to extend the general mandate to issue new shares. Shareholders may appoint representatives to attend the general meeting and vote. The proxy form must be submitted at least 48 hours prior to the general meeting at the Company's Hong Kong Share Registration Office.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more